

Dopamine Antagonists Ameliorate the Dyskinesias, Aggression, and Inattention of Persons with Mental Retardation Referred to Psychiatric Clinics

James Robert Brašić^{1,2}, Jacqueline Y. Barnett², Richard Zelfhof³, and Hugh Tarpley³

¹Division of Nuclear Medicine, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland

²Department of Psychiatry, Bellevue Hospital Center and the New York University School of Medicine, New York, New York

³Office of Mental Retardation and Developmental Disabilities of the State of New York, New York, New York

Corresponding author: James Robert Brašić, M. D., M. P. H., Division of Nuclear Medicine, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Johns Hopkins Outpatient Center, 601 North Caroline Street, Room 3245, Baltimore, Maryland 21287-0807, United States of America, brasic@jhmi.edu

Abstract

Background: Although dopamine antagonists are often administered to people with mental retardation, the neuropsychiatric effects are controversial. **Objective:** To characterize the effect of dopamine antagonists on movements and behaviors of persons with mental retardation. **Method:** Dyskinesias and behavioral problems are assessed in nine people with mental retardation referred to psychiatric clinics, including five men treated with dopamine antagonists in a dosage range equivalent to 67 to 220 mg chlorpromazine, and two men and two women who receive no medication during the preceding three months. **Results:** The nonmedicated subjects have higher levels of akathisia, stereotypies, tics, and other dyskinesias and lower global adaptive functioning. Utilizing the Mann-Whitney Test, nonmedicated subjects have more tics ($P < .006$), attention deficit disorder ($P < .018$), and overt aggression ($P < .015$); however, the Bonferroni correction for multiple comparisons renders all results nonsignificant. **Conclusions:** Dopamine antagonists ameliorate the dyskinesias, aggression, and inattention of some persons with mental retardation and behavioral problems. However, beneficial effects of dopamine antagonists must be weighed against adverse effects including withdrawal and tardive dyskinesias.

Key Words: aggression, attention, dyskinesias, mental retardation, stereotypies, tics

This research was supported by the Medical Fellows Program of the Consortium for Medical Education in Developmental Disabilities (CMEDD) of the Office of Mental Retardation and Developmental Disabilities (OMRDD) of the State of New York, the Essel Foundation, and the National Alliance for Research on Schizophrenia and Depression (NARSAD). This work was sponsored by the Department of Psychiatry at Bellevue Hospital Center and the New York University School of Medicine (Gaman J Psychiatry 2001; 4: 9-16).

Received: 15.04.2001

Published: 15.06.2001

Introduction

The beneficial and adverse effects of dopamine antagonists for individuals with mental retardation presenting at psychiatric clinics remain a topic of controversy. While multiple surveys in several locations have documented that 20-51%

of people with mental retardation and other developmental disabilities in the United States of America receive psychoactive medications (Brašić et al., 1997c; 2000b), the efficacy of those pharmacologic interventions is uncertain. Although the benefits of the administration of dopamine antagonists to people with developmental disabilities are not established, there is evidence that people with developmental disabilities are at risk for adverse effects, including tardive and withdrawal dyskinesias (Brašić and Bronson,

2001). Understanding the effects of dopamine antagonists on the movements and behaviors of people with developmental disabilities referred to psychiatric clinics can be facilitated by review of data about tardive dyskinesia in other psychiatric patients.

Tardive dyskinesia, particularly orofacial movements in association with negative symptoms, and cognitive impairments, may manifest brain damage (Perris et al., 1979) in individuals with schizophrenia (Manschreck, 1989; Manschreck et al., 1990; Sorokin et al., 1988; Waddington et al., 1987), bipolar disorder (Waddington et al., 1989), epilepsy (Youssef and Waddington, 1988), dementia (O'Keane and Dinan, 1991; Sweet et al., 1992; Ticehurst, 1990), and mental retardation (Gualtieri et al., 1986; Youssef and Waddington, 1988).

The emergence of tardive orofacial dyskinesia in psychiatric patients (Waddington et al., 1993) may be hastened by chronic treatment with neuroleptics (Jenner and Marsden, 1989). The hypothesis that a pre-existing neurodevelopmental syndrome (Jones and Murray, 1991) may be responsible for adventitious movements in schizophrenia is confirmed by surveys (Christensen et al., 1970; Edwards, 1970) that provide neurological and pathological evidence of brain damage among institutionalized patients with orofacial dyskinesia induced by neuroleptics, and is substantiated by the retrospective observation of verbally mediated learning deficits in psychiatric patients with tardive dyskinesia (Famuyiwa et al., 1979) and by the prospective observation of a high incidence of tardive dyskinesia in psychiatric patients with poor initial cognitive function (Struve and Willner, 1983; Waddington et al., 1990). Additional anatomic and psychological deficits are associated with tardive dyskinesia. For example, shortened left caudate T_2 relaxation time consistent with atrophy is identified in some schizophrenic patients who developed tardive dyskinesia (Bartzokis et al., 1990; Caligiuri et al., 1989; Mukherjee et al., 1991; Wilson et al., 1984). Furthermore, poor performance on neuropsychological tests of frontal lobe function is associated with tardive dyskinesia in a group of chronic schizophrenic patients (Brown et al., 1992).

Nevertheless, evidence of anosognosia and affective symptoms in some individuals with tardive dyskinesia suggest that other regions of the brain are involved in tardive dyskinesia (Myslobodsky, 1986). The cognitive deficits in tardive dyskinesia may represent a form of subcortical dementia (Gilleard and Vaddadi, 1986) or frontal lobe dysfunction (Wade et al., 1988).

Additionally, limb-truncal dyskinesia has been described in terms of a pathophysiologically and functionally discernible topographic tardive dyskinesia subtype. Schizophrenics with limb-truncal dyskinesia have been shown to demonstrate greater attentional and other cognitive dysfunction (Paulsen et al., 1994) and more negative symptoms (Brown and White, 1992; Brown et al., 1992) than those with orofacial dyskinesia.

A group of eight subjects with mental retardation manifested orofacial dyskinesias and diffuse impairments in motor control. Orofacial dyskinesias, stereotypies, and tics were more severe in the

four unmedicated subjects and less severe in the four subjects who had been treated with dopamine receptors antagonists (Barnett and Brašić, 1995).

Based on our earlier study of medicated and unmedicated subjects with mental retardation (Barnett and Brašić, 1995) and the evidence for a predisposition to movement disorders and cerebral dysfunction in people with mental disorders excluding mental retardation, we hypothesize that some individuals with mental retardation possess an innate vulnerability to exhibit movement and behavioral disorders that is alleviated by dopamine antagonists. By expanding and refining our original sample, we seek to compare and contrast the dyskinesias, general social adjustment, and comorbid behavior disorders in two groups of individuals with mental retardation, one treated with neuroleptic medication and the other non-medicated (Brašić et al., 1998c).

Methods

Subjects

For three years subjects are recruited for this study from an urban psychiatric clinic for adults with mental retardation at a state developmental disabilities office and from a developmental disabilities clinic serving children, adolescents, and adults in the psychiatric department of a tertiary-care municipal hospital. The building that housed the psychiatric clinic at the state developmental disabilities office was an intermediate care facility (ICF) for approximately 200 people with mental retardation (MR) during the initial years of the study. The ICF closed during the course of the study resulting in placement of all the residents of the ICF in community residences, other institutions, or other settings during the course of the study. The psychiatric clinic continued to operate while the building was renovated from residential units to offices. Most of the patients referred to the psychiatric clinic in the state developmental disabilities office were adults. Because of the specialized services offered at the psychiatry clinic in the state developmental disabilities office, some patients were referred from other neighboring regions for consultation. However, most of the patients attending the psychiatric clinic at the state developmental disabilities office had originally resided at the ICF for people with MR. The developmental disabilities clinic in the psychiatric department of the municipal hospital offered highly specialized services resulting in referrals from neighboring states. Most of the patients in the developmental disabilities clinic in the municipal hospital were children. In both clinics subjects were referred by clinicians, including psychologists and pediatricians, who identified

emotional and behavioral problems, including depression and aggression, in need of specialized psychiatric consultation for diagnosis and treatment.

All adolescents and adults who registered in both clinics were eligible for this study. Head trauma resulting in loss of consciousness led to exclusion. In order to be included in the study, subjects were required to complete both the clinic evaluation, a process involving several clinic visits, and an additional neuropsychological evaluation (Barnett and Brašić, 1995; Barnett et al., 1998) requiring at least one additional two-hour session. Since the neuropsychological evaluation required the spoken responses of the subjects, all subjects for this study were verbal adults who cooperated with the neuropsychologist to complete the full neuropsychological battery. The results of the neuropsychological assessments will be published separately.

The subjects are nine adults who fulfilled contemporary criteria for mild or moderate mental retardation (American Psychiatric Association, 1994). In order to enlarge the original sample, one medicated man and one unmedicated man were added to the study. In order to eliminate atypical cases, we omitted the only adolescent, a girl, from the original group (Barnett and Brašić, 1995).

The subjects include five men (mean \pm standard deviation (SD) age=33 \pm 10; intelligence quotient (IQ) = 60 \pm 7) treated with dopamine antagonists in a dosage range equivalent to 67 to 220 mg chlorpromazine and two men and two women with mental retardation (age=29 \pm 7; IQ = 60 \pm 4) who received no medication during the three months preceding evaluation except for one person who received a single dose of amitriptyline during the month before the evaluation. The five medicated subjects received neuroleptics for at least three months; one additionally received lithium carbonate. The non-medicated subjects had received thioridazine and/or benzodiazepines for less than a month over the year preceding the evaluation.

Adventitious movements, including akathisia, stereotypies, tics, and other dyskinesias, are rated independently in person by a neuropsychologist and three psychiatrists in a nonblind manner. To assess movements, the raters observe the subjects following the protocols of the Abnormal Involuntary Movement Scale (AIMS) (Brašić and Bronson, 2001; Guy, 1976), the Hillside Akathisia Scale (HAS) (Brašić and Bronson, 2001; Fleischhacker et al., 1989), and the Timed Stereotypies Rating Scale (TSRS) (Brašić and Bronson, 2001; Campbell, 1985). Subjects are rated on the basis of the observed clinical rating session lasting approximately 30 minutes. Subjects are rated solely on the basis of their performance in the assessment period. Due to the inability of the subjects and their caregivers to provide accurate historical data, no interview about past functioning is attempted for this study. The administration of rating instruments is modified to omit the clinical interview to elicit information about current and past movements and behavior that is part of the assessment protocol for several instruments utilized (Leckman et al., 1988, 1989; Simpson et al.,

1979). Therefore, all assessments are based solely on the observed behavior of the subject during the clinical assessment session. Thus, the administration of several instruments is modified to match the capabilities of patients with severe cognitive limitations by omitting an interview of subject and family to determine current and past functioning (Barnett and Brašić, 1995; Brašić, 2000, 2001a, b; Brašić and Barnett, 1997; Brašić and Gianutsos, 2000; Brašić et al., 1994, 1996, 1997a,b, 1998a,b, c, 1999, 2000a,c). General dyskinesias are assessed using the Abnormal Involuntary Movement Scale (AIMS) (Brašić and Bronson, 2001; Guy, 1976) and the Tardive Dyskinesia Rating Scale (TDRS) (Simpson et al., 1979). Akathisia is evaluated with the Hillside Akathisia Scale (HAS) (Brašić and Bronson, 2001; Fleischhacker et al., 1989) and the Rating Scale for Drug-Induced Akathisia (RSDIA) (Barnes, 1989). Stereotypies are assessed with the Timed Stereotypies Rating Scale (TSRS) (Brašić and Bronson, 2001; Campbell, 1985). Tics are evaluated utilizing the Yale Global Tic Severity Scale (YGTSS) (Leckman et al., 1989) and the Clinical Global Impressions Scale for Tourette's Syndrome (CGISTS) (Leckman et al., 1988). Obsessions and compulsions are assessed by the Clinical Global Impressions Scale for Obsessive-Compulsive Disorder (CGIS OCD) (Leckman et al., 1988). Attentional problems are evaluated by the Clinical Global Impressions Scale for Attention Deficit Disorder (CGISADD) (Leckman et al., 1988). Aggression is assessed with the Modified Overt Aggression Scale (MOAS) (Kay et al., 1988). Overall adaptive functioning is assessed utilizing the Children's Global Assessment Scale (CGAS) (Shaffer et al., 1983, 1985).

Statistical Analysis

The Chi-Square, Mann-Whitney, and Sign Tests were performed for between-group comparisons of independent samples. Pearson's Product Moment Correlation was utilized to assess the strength of association (Conover, 1980).

Results

Demographic and personal characteristics

Utilizing the Chi-Square (χ^2) Test for differences in probabilities (Conover, 1980), there are no significant differences in gender ($\chi^2=0.287$, 1 df, $P=0.750$) and handedness ($\chi^2=0.032$, 1 df, $P=0.750$) between the medicated and non-medicated groups. Utilizing the Mann-Whitney Test (Conover, 1980), there are no significant differences in age (Mann Whitney Test Statistic = 0.137, $P=0.555$)

and intelligence quotient (Mann Whitney Test Statistic = 0, $P = 0.500$) between the medicated and non-medicated groups.

Behavioral assessment

Overall adaptive functioning is impaired in both groups equally on the CGAS (Shaffer et al., 1983, 1985), the CGISADD (Leckman et al., 1988), and the CGISOCD (Leckman et al., 1988) in both medicated and nonmedicated subjects. Behavioral assessments do not discriminate medicated and non-medicated groups.

Abnormal movements

Orofacial dyskinesia is diagnosed by a rating of 2 or higher on any one of the AIMS (Brašić and Bronson, 2001; Guy, 1976) items concerning the mouth and face. Three (75%) of the four nonmedicated subjects and three (60%) of the five medicated subjects exhibit orofacial dyskinesias utilizing the AIMS (Brašić and Bronson, 2001; Guy, 1976). Limb-truncal dyskinesia is diagnosed by a rating of 2 or higher on any of the AIMS (Brašić and Bronson, 2001; Guy, 1976) items concerning the limbs and trunk. One (25%) of the four nonmedicated subjects and one (20%) of the five medicated subjects exhibit limbtruncal dyskinesias on the AIMS (Brašić and Bronson, 2001; Guy, 1976). Overall tardive dyskinesia is diagnosed by any rating of 2 or higher on any item of the AIMS concerning the mouth, face, limbs or trunk (Brašić and Bronson, 2001; Guy, 1976).

Limb-truncal dyskinesia ratings are obtained from the mean scores of the extremity and trunk items of the AIMS (Brašić and Bronson, 2001; Guy, 1976).

In particular, orofacial dyskinesias are more prominent than limbtruncal dyskinesias in the nonmedicated subjects utilizing the AIMS (Brašić and Bronson, 2001; Guy, 1976) (Pearson's Product Moment Correlation $r = 0.0356$) (Conover, 1980). However, this finding is not confirmed utilizing the Sign Test (Conover, 1980) to test if the orofacial scores are higher than limbtruncal scores of the AIMS (Brašić and Bronson, 2001; Guy, 1976), TSRS (Brašić and Bronson, 2001; Campbell, 1985), and TDRS (Simpson et al., 1979).

Table 1. Probability Values by the Mann-Whitney Test (Conover, 1980) that Scores on the Abnormal Involuntary Movement Scale (AIMS) (Brašić and Bronson, 2001; Guy, 1976) Are Higher in Four Adults with Mental Retardation Referred to Psychiatric Clinics and Treated without Neuroleptics than in Five Adults with Mental Retardation Referred to Psychiatric Clinics and Treated with Neuroleptics

AIMS Category	Mann-Whitney Test Statistic	Probability Value
Orofacial	1.112	0.134
Limb-truncal	1.572	0.058
Severity	1.414	0.079

Table 2. Probability Values by the Mann-Whitney Test (Conover, 1980) that Akathisia Scores on the Hillside Akathisia Scale (HAS) (Brašić and Bronson, 2001; Fleischhacker et al., 1989), the Rating Scale for Drug-Induced Akathisia (RSDIA) (Barnes, 1989), and the Rating Scale for Tardive Dyskinesia (RSTD) (Simpson et al., 1979) Are Greater in Four Adults with Mental Retardation and Behavioral Problems Treated without Neuroleptics than in Five Adults with Mental Retardation and Behavioral Problems Treated with Neuroleptics

Instrument	Mann-Whitney Test Statistic	Probability Value
HAS Objective	1.246	0.107
RSDIA Objective	1.549	0.061
RSTD Face	0.122	0.452
RSTD Neck and Trunk	0.615	0.271
RSTD Upper Extremity	0.371	0.356
RSTD Lower Extremity	0.997	0.150
RSTD Entire Body	0.884	0.189

Scores for general dyskinesias (Brašić and Bronson, 2001; Guy, 1976) (Table 1), akathisia (Barnes, 1989; Brašić and Bronson, 2001; Fleischhacker et al., 1989; Simpson et al., 1979) (Table 2), stereotypies (Brašić and Bronson, 2001; Campbell, 1985), tics (Leckman et al., 1988, 1989), attention deficit disorder (Leckman et al., 1988), obsessive compulsive disorder (Leckman et al., 1988), and aggression (Kay et al., 1988) were all greater in non-medicated patients. However, no significant differences were observed except for the following findings. Utilizing the Mann-Whitney Test, the nonmedicated subjects had higher scores than the medicated subjects on the CGISTS (Leckman et al., 1988) (Mann Whitney Test Statistic = 2.513, $P < 0.006$) (Conover, 1980), the CGISADD (Mann Whitney Test Statistic = 2.109, $P < 0.018$) (Conover, 1980) and the MOAS (Kay et al., 1988) (Mann Whitney Test Statistic = 2.196, $P < 0.015$) (Conover, 1980). However, if the Bonferroni criterion is employed to correct for multiple comparisons, all differences are attenuated to nonsignificance. Scores for overall adaptive functioning (Shaffer et al., 1983, 1985) were higher, but not significantly higher, utilizing the Mann-Whitney Test (Conover, 1980), for medicated patients; this is consistent with the other findings because a higher score on the CGAS (Shaffer et al., 1983,

1985) indicates better behavior while a higher score on all the other instruments indicates worse behavior.

Discussion

Five participants with mental retardation referred to psychiatric clinics and treated with neuroleptics were compared and contrasted with four participants with mental retardation referred to psychiatric clinics and treated without neuroleptics for at least three months. Based on unblinded assessments using previously published rating scales, the neuroleptic-treated participants demonstrated less akathisia, stereotypies, tics, attention deficit, and aggression.

In this retrospective study, the prevalence of orofacial dyskinesia (60-75%) in this sample of young adults with mental retardation exceeds the range of the prevalence of orofacial dyskinesia (17% to 34%) previously reported in neuroleptic-exposed populations of individuals with developmental disabilities under 60 years of age (Cohen et al., 1991; Gualtieri et al., 1986; Youssef and Waddington, 1988). Additionally, idiopathic orofacial dyskinesia was significantly worse than limb-truncal dyskinesia in 75% of subjects with mental retardation either never exposed or exposed to a low dose for a short time. This prevalence is comparable to that in senile dementia (O'Keane and Dinan, 1991) and Down syndrome (Dinan and Golden, 1990; Kohen and Mathew, 1990). These findings suggest that some people with mental retardation may exhibit a vulnerability to dyskinesia, particularly orofacial dyskinesia. People with mental retardation may be vulnerable to develop dyskinesias, particularly orofacial, in response to a variety of trauma, including exposure to and/or withdrawal from dopamine antagonists. Since some participants in the nonmedicated group had previously received neuroleptics, although not in the three months preceding the study, some observed dyskinesias may represent tardive dyskinesias secondary to prior administration of the dopamine receptor blocking drugs (Brašić and Bronson, 2001). The medicated subjects may have manifested fewer dyskinesias due to a salutatory effect of the neuroleptics. Administration of neuroleptics may prevent the dyskinesias by blocking post-synaptic dopamine receptors. Long-term administration of neuroleptics, however, may lead to upregulation of the post-synaptic dopamine receptors and supersensitization to dopamine resulting in further dyskinesias. While administration of neuroleptics may suppress dyskinesias in people with mental retardation, the beneficial effect must be balanced against adverse effects including the development of severe permanent withdrawal and tardive dyskinesias.

Non-medicated patients manifested more aggression, attention deficit, and tics than the medicated patients. Thus, we conclude that dopamine receptor antagonists may provide protection against

these behavioral and movement disorders in some persons with mental retardation. These results suggest that dysregulation of central dopamine may contribute to aggression, lack of attention, and tics in persons with mental retardation. While acute benefits are likely to result when people with mental retardation are given dopamine receptors antagonists, long-term treatment may result in the development of intractable movement disorders, including withdrawal and tardive dyskinesias (Brašić and Bronson, 2001). An alternative explanation is that the medicated sample had fewer problems with aggression, attention deficits, and tics than the non-medicated group at baseline.

The several limitations of this study must be addressed in order to put the findings in the context of the published literature. This was a retrospective study so it is not known whether the treated and untreated patients had comparable levels of movements, attention deficit, and aggression before treatment with neuroleptics. Also non-medicated subjects in this study had received prior treatment with thioridazine and benzodiazepines, although not in the three months preceding the assessment. Thus, the baseline ratings of the non-medicated subjects before they ever received psychoactive medications are unknown. Therefore, non-medicated subjects may have manifested neuropsychiatric effects of earlier treatment with psychoactive medications. It is unknown if the medicated and non-medicated subjects in this study had comparable levels of neuropsychiatric conditions, including dyskinesias and aggression, initially before ever receiving medication; the medicated participants may actually have fewer disturbances including dyskinesias and aggression originally. Another limitation to the study is the use of scales suitable to assess specific movement disorders, e. g., akathisia (Barnes, 1989; Brašić and Bronson, 2001; Fleischhacker et al., 1989), stereotypies (Brašić and Bronson, 2001; Campbell, 1985), and tics (Leckman et al., 1988, 1989). The scales do not distinguish different movements in the same patient. Distinguishing among types of movement required clinical judgment. Future studies of larger sample sizes of subjects with only single movement disorders would help to clarify the presence of movements and behavioral phenomena in those groups.

The subjects represent those adults with mental retardation attending psychiatric clinics for those with developmental disabilities who completed the extensive neuropsychological testing battery in addition to the complete clinical evaluation. Therefore, the findings need confirmation through prospective studies with larger samples at multiple centers. A preferable design for future studies is the assessment of blinded videotapes of the same groups of subjects before and after specific durations of treatment with specific neuroleptics. Future studies to confirm the findings with medicated subjects and never medicated subjects are needed. Additionally visualization of neurotransmitters in the brains of subjects before and during treatment with medications is needed to clarify the effects of the interventions. The neuroimaging protocols that identify deficits in other neuropsychiatric disorders (Brašić and

Wong, 2001; Wong and Brašić, 2001) are being applied to mental retardation and other developmental disabilities to clarify the disturbances in neurotransmitter pathways..

Acknowledgements

This research was supported by the Medical Fellows Program of the Consortium for Medical Education in Developmental Disabilities (CMEDD) of the Office of Mental Retardation and Developmental Disabilities (OMRDD) of the State of New York, the Essel Foundation, and the National Alliance for Research on Schizophrenia and Depression (NARSAD). This work was sponsored by the Department of Psychiatry of Bellevue Hospital Center and the New York University School of Medicine. We gratefully acknowledge the cooperation of the Health and Hospitals Corporation of the City of New York. An earlier version of this paper was presented at the Fifth International Congress of Parkinson's Disease and Movement Disorders in New York City on October 13, 1998 (Brašić et al., 1998c).

References

- American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association 1994
- Barnes TRE. A Rating Scale for Drug-Induced Akathisia. *Br J Psychiatry* 1989;154:672-676
- Barnett JY, Brašić JR. Movement disorders and cognitive deficits in mental retardation. *Archives of Clinical Neuropsychology* 1995;10:296-297 [abstract]
- Barnett JY, Brašić JR, Zelhof R, Tarpley H. Neurocognitive correlates of dyskinesia in cocaine abstinent adults with mental retardation. *Mov Disord* 1998;13 (supplement 2): 223 [abstract]
- Bartzokis G, Garber HJ, Marder SR, Olendorf WH. MRI in tardive dyskinesia: shortened left caudate T₂. *Biol Psychiatry* 1990;28:1027-1036
- Brašić JR. Differentiating myoclonus from tics. *Psychol Rep* 2000;86:155-156
- Brašić JR. Pervasive developmental disorder: Asperger syndrome. In: Berkowitz CD, Konop R, Pataki C, Steiner H, Kappelman MM (eds) *Emedicine: pediatrics*. Saint Petersburg, Florida: Emedicine.com, Inc.; 2001a <http://www.emedicine.com/ped/topic147.htm>
- Brašić JR. Pervasive developmental disorder: autism. In: Berkowitz CD, Konop R, Pataki C, Steiner H, Kappelman MM (eds) *Emedicine: pediatrics*. Saint Petersburg, Florida: Emedicine.com, Inc.; 2001b <http://www.emedicine.com/ped/topic180.htm>
- Brašić JR, Barnett JY. Hyperkinesias in a prepubertal boy with autistic disorder treated with haloperidol and valproic acid. *Psychol Rep* 1997;80:163-170
- Brašić JR, Barnett JY, Ahn SC, Roncoli M, Nadrich RH, Ahmad R. Characterization of movement disorders in prepubertal boys with autistic disorder. *Mov Disord* 1996;11(Suppl 1):59 [abstract]
- Brašić JR, Barnett JY, Aisemberg P, Ahn SC, Nadrich RH, Kaplan D, Ahmad R, Mendonça MF. Dyskinesias subside off all medication in a boy with autistic disorder and severe mental retardation. *Psychol Rep* 1997a; 81:755-767
- Brašić JR, Barnett JY, Kaplan D, Sheitman BB, Aisemberg P, Lafargue RT, Kowalik S, Clark A, Tsaltas MO, Young JG. Clomipramine ameliorates adventitious movements and compulsions in prepubertal boys with autistic disorder and severe mental retardation. *Neurology* 1994;44:1309-1312
- Brašić JR, Barnett JY, Sheitman BB, Lafargue RT, Ahn SC. Clinical assessment of adventitious movements. *Psychol Rep* 1998a;83:739-750
- Brašić JR, Barnett JY, Sheitman BB, Lafargue RT, Kowalik S, Kaplan D, Tsaltas MO, Ahmad R, Nadrich RH, Mendonça MF. Behavioral effects of clomipramine on prepubertal boys with autistic disorder and severe mental retardation. *CNS Spectrums: The International Journal of Neuropsychiatric Medicine* 1998b;3(10):39-46
- Brašić JR, Barnett JY, Sheitman BB, Tsaltas MO. Adverse effects of clomipramine. *J Am Acad Child Adolesc Psychiatry* 1997b;36:1165-1166 [letter]
- Brašić JR, Barnett JY, Will MV, Nadrich RH, Sheitman BB, Ahmad R, Mendonça MF, Kaplan D, Brathwaite C. Dyskinesias differentiate autistic disorder from catatonia. *CNS Spectrums: The International Journal of Neuropsychiatric Medicine* 2000a;5(12):19-22
- Brašić JR, Barnett JY, Zelhof R, Tarpley H. Drugs that block dopamine receptors reduce dyskinesias and aggression and improve attention in individuals with mental retardation. *Mov Disord* 1998c;13(supplement 2):224 [abstract]
- Brašić JR, Bronson B: Tardive dyskinesia. In: Jacobs DH, Talavera F, GalvezJimenez N, Benbadis SR, Lorenzo NY (eds) *Emedicine: neurology*. Saint Petersburg, Florida: emedicine.com, Inc.; 2001 <http://www.emedicine.com/neuro/topic362.htm>
- Brašić JR, Furman J, Conte RM, Baisley WE, Jaslow RI. Assuring the quality of the utilization of psychoactive medication by people with mental retardation and developmental disabilities by assessing dosages. *German Journal of*

- Psychiatry 2000b;3(3):7-12 <http://www.gwdg.de/~bbandel/gjp-article-brasic2>
- Brašić JR, Gianutsos JG. Neuromotor Assessment and Autistic Disorder. *Autism: An International Journal of Research and Practice* 2000;4(3):287-298
- Brašić JR, Wong DF. PET scanning in autism spectrum disorders. In: Louis S, Talavera F, Mack KJ, Benbadis SR, Lutsep HL (eds) *Emedicine: neurology*. Saint Petersburg, Florida: Emedicine.com, Inc.; 2001 <http://www.emedicine.com/neuro/topic440.htm>
- Brašić JR, Young JG, Furman J, Conte RM, Baisley WE, Jaslow RI. Psychoactive Medication Quality Assurance Rating Survey (PQRS). *Journal of Developmental and Physical Disabilities* 1997c;9(4):311-336
- Brašić JR, Zagzag D, Kowalik S, Prichep L, John ER, Barnett JY, Bronson B, Nadrich RH, Cancro R, Buchsbaum M, Brathwaite C. Clinical manifestations of progressive catatonia. *German Journal of Psychiatry* 2000c;3 (2):13-24 <http://www.gwdg.de/~bbandel/gjp-article-brasic.htm>
- Brašić JR, Zagzag D, Kowalik S, Prichep L, John ER, Liang HG, Klutchko B, Cancro R, Sheitman BB, Buchsbaum M, Brathwaite C. Progressive catatonia. *Psychol Rep* 1999;84:239-246
- Brown KW, White T. The influence of topography on the cognitive and psychopathological effects of tardive dyskinesia. *Am J Psychiatry* 1992;149:1385-1389
- Brown KW, White T, Palmer D. Movement disorders and psychological tests of frontal lobe function in schizophrenic patients. *Psychol Med* 1992;22:69-77
- Caligiuri MP, Bracha HS, Lohr JB. Asymmetry of neuroleptic-induced rigidity: development of quantitative methods and clinical correlates. *Psychiatry Res* 1989;30:275-284
- Campbell M. Timed Stereotypies Rating Scale. *Psychopharmacol Bull* 1985;21:1082
- Christensen E, Moller J, Faurbye A. Neuropathological investigation of 28 brains from patients with dyskinesia. *Acta Psychiatr Scand* 1970;46:14-23
- Cohen S, Khan A, Zheng Y, Chiles J. Tardive dyskinesia in the mentally retarded: comparison of prevalence, risk factors and topography with a schizophrenic population. *Acta Psychiatr Scand* 1991;83:234-237
- Conover WJ. *Practical Nonparametric Statistics*, 2nd ed. New York: John Wiley & Sons, 1980
- Dinan TG, Golden T. Orofacial dyskinesia in Down's syndrome. *Br J Psychiatry* 1990;157:131-132
- Edwards H. The significance of brain damage in persistent oral dyskinesia. *Br J Psychiatry* 1970; 116:271-275
- Famuyiwa OO, Eccleston D, Donaldson AA, Garside RF. Tardive dyskinesia and dementia. *Br J Psychiatry* 1979;135:500-504
- Fleischhacker WW, Bergmann KJ, Perovich R, Pestreich LK, Borenstein M, Leiberman JA, Kane JK. The Hillside Akathisia Scale: a new rating instrument for neuroleptic-induced akathisia. *Psychopharmacol Bull* 1989;25:222-226
- Gilleard CJ, Vaddadi KS. Mood, memory, and motor performance and the severity of tardive dyskinesia. *Percept Mot Skills* 1986;63:1037-1038
- Gualtieri CT, Schroeder SR, Hicks RE, Quade D. Tardive dyskinesia in young mentally retarded individuals. *Arch Gen Psychiatry* 1986;43:335-340
- Guy W. *ECDEU assessment manual for psychopharmacology*, revised, 1976 (DHEW Publication No. ADM 76-338). Washington, DC: United States Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration; 1976: 534-537
- Jenner P, Marsden CD. Are the effects of chronic neuroleptic therapy different from those occurring on acute administration? In: Schulz SC, Tamminga CA (eds) *Schizophrenia: scientific progress*. New York: Oxford University Press; 1989:387-395
- Jones P, Murray RM. The genetics of schizophrenia is the genetics of neurodevelopment. *Br J Psychiatry* 1991;158:615-623
- Kay SR, Wolkenfeld F, Murrill LM. Profiles of aggression among psychiatric patients. I. Nature and prevalence. *J Nerv Ment Dis* 1988;176:539-546
- Kohen D, Mathew G. Dyskinesia in the mentally handicapped. *Br J Psychiatry* 1990;157:621 [letter]
- Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, Cohen DJ. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. *J Am Acad Child Adolesc Psychiatry* 1989;28:566-573
- Leckman JF, Towbin KE, Ort SI, Cohen DJ. Clinical assessment of tic disorder severity. In: Cohen DJ, Bruun RD, Leckman JF (eds) *Tourette's syndrome and tic disorders*. New York: John Wiley & Sons; 1988:55-78
- Manschreck TC. Motor and cognitive disturbances in schizophrenic disorders. In: Schulz SC, Tamminga CA (eds) *Schizophrenia: scientific progress*. New York: Oxford University Press; 1989:372-380
- Manschreck TC, Keuthen NJ, Schneyer ML, Celada ML, Laughery J, Collins P. Abnormal involuntary movements and chronic schizophrenic disorders. *Biol Psychiatry* 1990; 27:150-158
- Mukherjee S, Prohovnick I, Reddy R, Schnur DB. Persistent tardive dyskinesia, caudate atrophy on CT scan and regional blood flow findings in schizophrenia. *Schizophr Res* 1991;4:365 [abstract]

- Myslobodsky MS. Anosognosia in tardive dyskinesia: "tardive dysmentia" or "tardive dementia"? *Schizophr Bull* 1986;12:1-6
- O'Keane V, Dinan TG. Orofacial dyskinesia and senile dementia of the Alzheimer type. *International Journal of Geriatric Psychiatry* 1991;6:41-44
- Paulsen JS, Heaton RK, Jeste DV. Neuropsychological impairment in tardive dyskinesia. *Neuropsychology* 1994;8:227-241
- Perris C, Dimitrijevic P, Jacobsson L, Paulsson P, Rapp W, Froberg H. Tardive dyskinesia in psychiatric patients treated with neuroleptics. *Br J Psychiatry* 1979;135:509-514
- Shaffer D, Gould MS, Brašić J, Ambrosini P, Fisher P, Bird H, Aluwahlia S. A Children's Global Assessment Scale (CGAS) *Arch Gen Psychiatry* 1983;40:1228-1231
- Shaffer D, Gould MS, Brašić J, Ambrosini P, Fisher P, Bird H, Aluwahlia S. A Children's Global Assessment Scale (CGAS) (for children 4 to 16 years of age). *Psychopharmacol Bull* 1985;21:747-748
- Simpson GM, Lee JH, Zoubok B, Gardos G. A rating scale for tardive dyskinesia. *Psychopharmacology* 1979;64:171-179
- Sorokin JE, Giordani B, Mohs RC, Losonczy MF, Davidson M, Siever LJ, Ryan TA, Davis KL. Memory impairment in schizophrenic patients with tardive dyskinesia. *Biol Psychiatry* 1988;23:129-135
- Struve FA, Willner AE. Cognitive function and tardive dyskinesia. *Br J Psychiatry* 1983;143:597-600
- Sweet RA, Mulsant BH, Rifai AH, Zubenko GS. Dyskinesia and neuroleptic exposure in elderly psychiatric inpatients. *J Geriatr Psychiatry Neurol* 1992;5:156-161
- Ticehurst SB. Is spontaneous orofacial dyskinesia an artefact due to incomplete drug history? *J Geriatr Psychiatry Neurol* 1990;3:208-211
- Waddington JL, Brown K, O'Neill J, McKeon P, Kinsella A. Cognitive impairment, clinical course and treatment history in out-patients with bipolar affective disorder: relationship to tardive dyskinesia. *Psychol Med* 1989;19:897-902
- Waddington JL, O'Callaghan E, Larkin C, Kinsella A. Cognitive dysfunction in schizophrenia: organic vulnerability factor or state marker for tardive dyskinesia? *Brain Cogn* 1993;23:56-70
- Waddington JL, Youssef HA, Dolphin C, Kinsella A. Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia: their association in relation to topography of involuntary movements and criterion of their abnormality. *Arch Gen Psychiatry* 1987;44:907-912
- Waddington JL, Youssef HA, Kinsella A. Cognitive dysfunction in schizophrenia followed up over 5 years, and its longitudinal relationship to the emergence of tardive dyskinesia. *Psychol Med* 1990;20:835-842
- Wade JB, Lehmann L, Hart R, Linden D, Novak T, Hamer R. Cognitive changes associated with tardive dyskinesia. *Neuropsychiatry Neuropsychol Behav Neurol* 1988;1:217-227
- Wilson RL, Waziri R, Nasrallah HA, McCalley-Whitters M. The lateralization of tardive dyskinesia. *Biol Psychiatry* 1984;19:629-635
- Wong DF, Brašić JR. In vivo imaging of neurotransmitter systems in neuropsychiatry. *Clinical Neuroscience Research* 2001;1:35-45
- Youssef HA, Waddington JL. Involuntary orofacial movements in hospitalised patients with mental handicap or epilepsy: relationship to developmental/intellectual deficit and presence or absence of long-term exposure to neuroleptics. *J Neurol Neurosurg Psychiatry* 1988;51:863-865